Are you ready for one of the most anticipated IPOs of 2024? Check out the latest on Emcure Pharmaceuticals IPO GMP (Grey Market Premium), Kostak rates, and Subject to Sauda rates. As of today, the Emcure Pharmaceuticals IPO GMP is ₹285, and the IPO is set to open on July 3.
Emcure Pharmaceuticals IPO Overview
Emcure Pharmaceuticals is a renowned name in the pharmaceutical industry, driven by innovation and a robust research and development (R&D) pipeline. The company is poised to raise ₹1952.03 crores through its IPO, with a price band fixed at ₹960 to ₹1008 and a market lot of 14 shares. Namita Thapar, the visionary leader of Emcure and a popular figure from Shark Tank India, brings immense credibility and excitement to this IPO.
Table of Contents
- What is Emcure Pharmaceuticals IPO GMP Today?
- What are Emcure Pharmaceuticals IPO Kostak Rates Today?
- What is Emcure Pharmaceuticals IPO Subject to Sauda Price Today?
- Why Should You Consider Investing in Emcure Pharmaceuticals IPO?
- Emcure Pharmaceuticals IPO Expected Returns
- Emcure Pharmaceuticals IPO GMP Live Rates Day-by-Day with Kostak Rates
- Emcure Pharmaceuticals IPO GMP FAQs
What is Emcure Pharmaceuticals IPO GMP Today?
The Emcure Pharmaceuticals IPO GMP (Grey Market Premium) is currently ₹285. This indicates strong market interest and potential for significant returns.
What are Emcure Pharmaceuticals IPO Kostak Rates Today?
The Emcure Pharmaceuticals IPO Kostak Rate stands at ₹-, indicating no significant off-market transactions for selling IPO applications before allotment.
What is Emcure Pharmaceuticals IPO Subject to Sauda Price Today?
The Subject to Sauda rates for Emcure Pharmaceuticals IPO is ₹3000, reflecting high demand and positive sentiment among investors.
Why Should You Consider Investing in Emcure Pharmaceuticals IPO?
- Leadership: Led by Namita Thapar, a respected entrepreneur and investor, Emcure Pharmaceuticals is set to leverage her extensive industry knowledge and Shark Tank fame.
- Strong R&D: Emcure’s focus on R&D has resulted in a diverse product portfolio, including orals, injectables, and biotherapeutics.
- Global Reach: With a presence in over 70 countries and strongholds in India, Europe, and Canada, Emcure has a vast market footprint.
- Financials: The IPO aims to raise ₹1952.03 crores, underscoring the company’s growth ambitions and robust financial health.
- Market Sentiment: A GMP of ₹285 and expected returns of 28% indicate strong market confidence and potential for lucrative gains.
Emcure Pharmaceuticals IPO Expected Returns
The expected return on Emcure Pharmaceuticals IPO is a promising 28%, making it an attractive investment opportunity.
Emcure Pharmaceuticals IPO GMP Live Rates Day-by-Day with Kostak Rates
| Date | IPO GMP | Kostak | Subject to Sauda |
|---|---|---|---|
| Today | ₹285 | ₹- | ₹3000 |
| 01 July | ₹260 | ₹- | ₹2500 |
| 30 June | ₹300 | ₹- | ₹2500 |
| 29 June | ₹300 | ₹- | ₹2500 |
| 28 June | ₹300 | ₹- | ₹2500 |
| 27 June | ₹- | ₹- | ₹- |
Emcure Pharmaceuticals IPO GMP FAQs
What is Emcure Pharmaceuticals IPO GMP Today? Emcure Pharmaceuticals IPO GMP is ₹285 as of today.
What is Emcure Pharmaceuticals IPO Kostak Rate Today? Emcure Pharmaceuticals IPO Kostak Rate is ₹- as of today.
What is Emcure Pharmaceuticals IPO Subject to Sauda Today? Emcure Pharmaceuticals IPO Subject to Sauda is ₹3000 as of today.
What is Emcure Pharmaceuticals IPO Expected Returns? Emcure Pharmaceuticals IPO Expected Returns is 28%.
Disclaimer:
IPO Grey Market Premium (Emcure Pharmaceuticals IPO GMP) mentioned is valid for the specific date as noted. We do not engage in buying and selling IPO forms on the Grey Market. Kostak Rate is the premium received by selling an IPO application before allotment or listing. Subscribe to the IPO based on fundamental analysis of the company rather than just the GMP.
Get ready to invest in Emcure Pharmaceuticals IPO and benefit from the expertise of Namita Thapar, who continues to inspire confidence and growth in the industry. Stay tuned for more updates and analysis on Emcure Pharmaceuticals IPO GMP.
